Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
REGN | NASDAQ | USD | Real-time | |
1REGN | Milan | EUR | Real-time | |
REGN | Frankfurt | EUR | Delayed | |
REGN | TradeGate | EUR | Delayed | |
REGN34 | B3 | BRL | Delayed | |
REGN | Vienna | EUR | Real-time | |
REGN | Lima | USD | Delayed |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Name | Age | Since | Title |
---|---|---|---|
Joseph L. Goldstein | 83 | 1991 | Independent Director |
George D. Yancopoulos | 63 | 1998 | Co-Founder, President, Chief Scientific Officer & Co-Chairman |
George L. Sing | 74 | 1988 | Independent Director |
Huda Y. Zoghbi | 68 | 2016 | Independent Director |
Christine Ann Poon | 71 | 2010 | Lead Independent Director |
Bonnie L. Bassler | 61 | 2016 | Independent Director |
N. Anthony Coles | 63 | 2017 | Independent Director |
Craig B. Thompson | 70 | 2022 | Independent Director |
David P. Schenkein | 66 | 2023 | Director |
Kathryn W. Guarini | - | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review